启迪药业(000590.SZ)发布2023年度业绩，净利润2524.68万元，增长39.41%

智通财经网03-27

启迪药业(000590.SZ)发布2023年年度报告，该公司营业收入为4.05亿元，同比增长15.44%。归属于上市公司股东的净利润为2524.68万元，同比增长39.41%。归属于上市公司股东的扣除非经常性损益的净亏损为465.05万元。基本每股收益为0.1054元。公告称，归属于上市公司股东的净利润比上年同期增长主要源于非经常性损益，主要包括：公司确认因公共基础设施建设被政府占用土地补偿收益、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2422998556?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-27 19:49","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2422998556","market":"sh","top_or_hot":-1,"title":"启迪药业(000590.SZ)发布2023年度业绩，净利润2524.68万元，增长39.41%","media":"智通财经网","content":"<div>\n<p>启迪药业(000590.SZ)发布2023年年度报告，该公司营业收入为4.05亿元，同比增长15.44%。归属于上市公司股东的净利润为2524.68万元，同比增长39.41%。归属于上市公司股东的扣除非经常性损益的净亏损为465.05万元。基本每股收益为0.1054元。公告称，归属于上市公司股东的净利润比上年同期增长主要源于非经常性损益，主要包括：公司确认因公共基础设施建设被政府占用土地补偿收益、...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-27/doc-inapumws3212797.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>启迪药业(000590.SZ)发布2023年度业绩，净利润2524.68万元，增长39.41%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n启迪药业(000590.SZ)发布2023年度业绩，净利润2524.68万元，增长39.41%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-27 19:49 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-27/doc-inapumws3212797.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>启迪药业(000590.SZ)发布2023年年度报告，该公司营业收入为4.05亿元，同比增长15.44%。归属于上市公司股东的净利润为2524.68万元，同比增长39.41%。归属于上市公司股东的扣除非经常性损益的净亏损为465.05万元。基本每股收益为0.1054元。公告称，归属于上市公司股东的净利润比上年同期增长主要源于非经常性损益，主要包括：公司确认因公共基础设施建设被政府占用土地补偿收益、...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-27/doc-inapumws3212797.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000590","symbol_name":"启迪药业","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-27/doc-inapumws3212797.shtml","article_id":"2422998556","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-27/doc-inapumws3212797.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2422998556","pubTimestamp":1711540140,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"启迪药业发布2023年年度报告，该公司营业收入为4.05亿元，同比增长15.44%。归属于上市公司股东的净利润为2524.68万元，同比增长39.41%。归属于上市公司股东的扣除非经常性损益的净亏损为465.05万元。基本每股收益为0.1054元。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"000590":"启迪药业"},"translate_title":"Qidi Pharmaceutical (000590. SZ) released its 2023 annual results with a net profit of 25.2468 million yuan, an increase of 39.41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000590":1},"content_text":"启迪药业(000590.SZ)发布2023年年度报告，该公司营业收入为4.05亿元，同比增长15.44%。归属于上市公司股东的净利润为2524.68万元，同比增长39.41%。归属于上市公司股东的扣除非经常性损益的净亏损为465.05万元。基本每股收益为0.1054元。公告称，归属于上市公司股东的净利润比上年同期增长主要源于非经常性损益，主要包括：公司确认因公共基础设施建设被政府占用土地补偿收益、子公司广东先通药业有限公司原股东未完成业绩承诺需向公司支付补偿、确认政府补助收益形成的非经常性损益增加等。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422998556"}